

Supplementary Materials

Anthelmintic A-Type Procyanidins and Further Characterization of the Phenolic Composition of a Root Extract from *Paullinia pinnata*

Verena Spiegler^{1*}

¹ Institute for Pharmaceutical Biology and Phytochemistry, University of Münster, Germany;
E-mail: verena.spiegler@uni-muenster.de

* Correspondence: verena.spiegler@uni-muenster.de

Table S1. ¹H and ¹³C NMR data of **1** and **2** (CD₃OD, 280 K).

Table S2: ¹H and ¹³C NMR data of **3a**, **4** and **5** (CD₃OD, 280 K).

Figure S1: MS/MS spectra and proposed fragmentation patterns (modified from [28]) of (a) compound **6** and (b) compound **1**.

Figure S2: +ESI-qTOF chromatograms of (a) compound **1**, (b) **1** after 72 h of incubation during the anthelmintic assay without addition of ascorbic acid and (c) plus 0.01 % ascorbic acid.

Figure S3 (a) – (f): 1D- and 2D-NMR spectra of compound **15**.

Figure S4 (a) – (f): 1D- and 2D-NMR spectra of compound **17**.

Figure S5 (a) – (f): 1D- and 2D-NMR spectra of compound **18**.

Figure S6 (a) – (d): 1D- and 2D-NMR spectra of compound **19**.

Figure S7: ¹H NMR spectrum of compound **1** (CD₃OD, 600 MHz, 280 K).

Figure S8: ¹H NMR spectrum of compound **2** (CD₃OD, 600 MHz, 280 K).

Figure S9: ¹H NMR spectrum of compound **3** (CD₃OD, 600 MHz, 280 K).

Figure S10: ¹H NMR spectrum of compound **3a** (CDCl₃, 600 MHz, 299 K).

Figure S11: ¹H NMR spectrum of compound **4** (CD₃OD, 600 MHz, 280 K).

Figure S12: ¹H NMR spectrum of compound **5** (CD₃OD, 600 MHz, 280 K).

Figure S13: ¹H NMR spectrum of compound **6** (CD₃OD, 600 MHz, 280 K).

Figure S14: ¹H NMR spectrum of compound **7** (CDCl₃, 600 MHz).

Figure S15: ¹H NMR spectrum of compound **8** (CDCl₃, 600 MHz).

Figure S16: ¹H NMR spectrum of compound **9** (CD₃OD, 600 MHz).

Figure S17: ¹H NMR spectrum of compound **10** (acetone-*d*₆, 600 MHz).

Figure S18: ¹H NMR spectrum of compound **11** (acetone-*d*₆, 600 MHz).

Figure S19: ¹H NMR spectrum of compound **12** (acetone-*d*₆, 600 MHz).

Figure S20: ¹H NMR spectrum of compound **13** (acetone-*d*₆, 600 MHz).

Figure S21: ¹H NMR spectrum of compound **14** (CD₃OD, 600 MHz).

Figure S22: ¹H NMR spectrum of compound **16** (D₂O, 600 MHz).

Table S1. ¹H and ¹³C NMR data of **1** and **2** (CD₃OD, 280 K).

Ring	No.	1		2	
		δ_C m	δ_H m (J/Hz)	δ_C m	δ_H m (J/Hz)
Unit I					
C	2	100.0, C		100.1, C	
	3	67.2, CH	3.27, d (3.5)	67.1, CH	3.31 *
A	4	28.8, CH	4.14 d (3.5)	29.0, CH	3.95, d (3.5)
	5	156.8, C		156.6, C	
	6	98.3, CH	5.96, d (2.4)	97.9, CH	5.84, d (2.4)
	7	157.8, C		158.0, C	
B	8	96.6, CH	6.00, d (2.4)	96.5, CH	5.99, d (2.4)
	9	154.2, C		154.0, C	
	10	104.9, C		104.1, C	
	1'	132.5, C		132.3, C	
	2'	115.8, CH	7.02, d (1.9)	115.7, CH	7.01, d (2.1)
	3'	145.8, C		145.3, C	
	4'	146.6, C		145.6, C	
Unit II	5'	115.7, CH	6.76*	115.7, CH	6.80, d (8.3)
	6'	119.9, CH	6.82, dd (8.2, 1.9)	119.8, CH	6.84 dd, (8.3, 2.3)
	2	78.9, CH	5.70, br s	84.54, CH	4.61, d (9.6)
F	3	72.6, CH	4.11 m	73.92, CH	4.56, d (9.5)
	4	38.3, CH	4.56 s	39.08, CH	4.51, d (8.8)
D	5	155.8, C		155.43, C	
	6	96.1, CH	5.79, s	97.2, CH	5.79, s
	7	151.1, C		151.2, C	
	8	106.4, C		106.9, C	
	9	151.8, C		152.3, C	
	10	106.7, C		109.0, C	
E	1'	131.8, C		131.1, C	
	2'	116.7, CH	7.32, d (2.0)	116.5, CH	7.19, d (2.0)
	3'	145.9, C		146.2, C	
	4'	146.3, C		146.7, C	
	5'	116.0, CH	6.84, d (8.2)	116.3, CH	6.89, d (8.1)
	6'	121.4, CH	7.20, dd (8.3, 2.0)	121.2, CH	7.14, dd (8.2, 2.0)
Unit III					
	2	80.3, CH	4.40, s	79.7, CH	4.37, brs
	3	67.5, CH	3.86, m	67.7, CH	4.07, d (4.4)
	4	29.9, CH ₂	2.83, m	30.1, CH ₂	2.87, dd (17.0, 4.9) 2.78, brd (16.9)
	5	156.0, C		156.25, C	
	6	96.4, CH	6.10, s	96.5, CH	6.08, s
	7	155.6, C		156.2, C	
	8	108.9, C		108.6, C	
	9	155.8, C		155.3, C	
	10	100.0, C		100.9, C	
	1'	133.2, C		133.0, C	
	2'	115.5, CH	6.83, d (1.7)	115.3, CH	6.98, d (1.9)
	3'	145.3, C		145.9, C	
	4'	145.5, C		146.7, C	
	5'	115.7, CH	6.82, d (8.2)	116.0, CH	6.83, d (8.2)
6'	119.4, CH	6.73*	119.3, CH	6.88, dd (8.3, 1.9)	

*Multiplicity not determined due to overlapping signals


Table S2: ¹H and ¹³C NMR data of **3a**, **4** and **5** (CD₃OD, 280 K).

Ring	No.	3a		4		Ring	No.	5	
		δ_C m	δ_H m (J/Hz)	δ_C m	δ_H m (J/Hz)			δ_C m	δ_H m (J/Hz)
Unit I						Unit I			
C	2	74.1, CH	5.55, brs	77.0, CH	4.94, s	C	2	100.1, C	
	3	70.8, CH	5.25, brt (1.5)	73.2, CH	3.86, d (3.8)		3	66.8, CH	3.28, d (3.6)
A	4	34.7, CH	4.68, s	37.3, CH	4.71, brs	A	4	28.9, CH	4.24, d (3.6)
	5	150.0, C ¹		157.9, C			5	156.7, C	
	6	110.2, CH	6.72, d (2.3)	96.4, CH	5.95, d (2.1)		6	98.3, CH	5.98, d (2.4)
	7	147.5, C ¹		158.2, C			7	157.9, C	
	8	107.9, CH	6.77, d (2.3)	96.0, CH	5.98, d (2.2)		8	96.5, CH	6.06, d (2.3)
	9	154.9, C		155.6, C			9	154.2, C	
B	10	111.1, C		101.8, C		B	10	104.9, C	
	1'	136.0, C		132.4, C			1'	132.3, C	
	2'	123.2, CH	7.53, d (2.2)	115.3, CH	6.81*		2'	115.8, CH	7.15, d (1.9)
	3'	142.0, C		145.5, C			3'	145.5, C	
	4'	143.2, C		145.8, C			4'	146.7, C	
	5'	123.5, CH	7.14, d (8.1)	115.8, CH	6.64, d (8.2)		5'	116.1, CH	6.89, d (8.3)
Unit II	6'	124.5, CH	7.24, dd (8.4, 1.9)	119.2, CH	6.53, dd (8.3, 1.0)	Unit II	6'	119.9, CH	6.91*
	F	2	97.3, C	100.3, C			F	2	78.7, CH
D	3	67.4, CH	5.00, d (3.9)	66.5, CH	3.40, d (3.4)	D	3	72.4, CH	4.06, brs
	4	28.0, CH	4.55, d (3.9)	29.1, CH	4.23, d (3.4)		4	38.4, CH	4.43, s
	5	148.0, C		155.4, C			5	154.2, C	
	6	117.5, C		99.5, CH	5.93, s		6	107.6, C	
	7	148.7, C		156.8, C			7	148.4, C	
	8	109.5, CH	7.01, s	108.3, C			8	106.9, C	
E	9	152.3, C		155.3, C		E	9	150.3, C	
	10	113.4, C		105.0, C			10	107.2, C	
	1'	135.3, C		132.4, C			1'	131.6, C	
	2'	125.5, CH	7.64, d (2.0)	115.6, CH	7.24, d (1.7)		2'	116.7, CH	7.31, d (2.0)
	3'	141.94, C		145.6, C			3'	145.9, C	
	4'	142.8, C		146.6, C			4'	146.3, C	
	5'	123.2, CH	7.27, d (8.6)	115.9, CH	6.83*		5'	115.9, CH	6.83, d (8.2)
	6'	125.3, CH	7.58, dd (8.6, 2.2)	120.0, CH	6.97, dd (8.3, 1.7)		6'	121.4, CH	7.22, dd (8.3, 2.0)

Unit III						Unit III			
I	2	76.3, CH	5.49, d (2.0)	78.9, CH	5.71, s	I	2	80.1, CH	4.10, d (2.3)
	3	70.2, CH	5.21, m	72.6, CH	4.11, brs		3	67.4, CH	3.61, m
G	4	33.7, CH	4.58, d (1.9)	38.4, CH	4.56, brs	G	4	29.7, CH ₂	2.78, brs
	5	150.0, C		155.9, C			5	155.5, C	
	6	104.9, CH	6.52, s	95.9, CH	5.74, s		6	96.5, CH	6.08, s
H	7	150.4, C		151.0, C		H	7	156.1, C	
	8	108.8, C		106.3, C			8	108.8, C	
	9	151.7, C		151.8, C			9	155.6, C	
	10	108.1, C		106.7, C			10	99.8, C	
	1'	134.6, C		131.7, C			1'	132.8, C	
	2'	121.9, CH	7.39, d (1.7)	116.7, CH	7.33, d (2.0)		2'	115.4, CH	6.64, d (1.9)
	3'	141.9, C		145.9, C			3'	145.7, C	
	4'	142.3, C		146.3, C			4'	145.4, C	
	5'	123.1, CH	7.11, d (8.3)	116.1, CH	6.84, d (8.3)		5'	115.8, CH	6.71, d (8.1)
	6'	125.7, CH	7.20, dd (8.5, 2.1)	121.4, CH	7.21, dd (8.3, 2.0)		6'	119.2, CH	6.25, dd (8.2, 1.7)
Unit IV						Unit II'			
L	2	76.8, CH	5.15, brs	80.2, CH	4.40, brs	L	2	76.6, CH	4.74, s
	3	65.5, CH	5.52, dt (4.7, 1.7)	67.6, CH	3.86, brs		3	71.2, CH	4.10, d (2.3)
	4	26.5, CH ₂	3.05, dd (18.0, 4.6) 2.97, brd (18.0)	29.9, CH ₂	2.83, brs		4	37.6, CH	4.38, s
J	5	148.7, C		156.0, C		J	5	159.4, C	
	6	111.0, CH	6.58, s	96.2, CH	6.10, s		6	96.6, CH	5.88, d (2.3)
	7	147.5, C		155.8, C			7	159.6, C	
	8	118.5, C		108.8, C			8	96.1, CH	5.93, d (2.3)
	9	151.9, C		155.9, C			9	158.0, C	
	10	110.3, C		99.8, C			10	99.2, C	
K	1'	135.6, C		133.1, C		K	1'	131.6, C	
	2'	121.6, CH	7.25, d (1.9)	115.3, CH	6.81*		2'	116.8, CH	7.11, d (1.3)
	3'	141.6, C		145.4, C			3'	145.9, C	
	4'	142.0, C		145.8, C			4'	146.3, C	
	5'	123.2, CH	7.15, d (8.0)	115.9, CH	6.80*		5'	116.1, CH	6.91*
	6'	123.5, CH	7.13, dd (8.4, 1.9)	119.3, CH	6.75, dd (8.3, 2.4)		6'	120.7, CH	6.92*

¹Interchangeable. * Multiplicity not determined due to overlapping signals.

(a)



(b)




Figure S1: MS/MS spectra and proposed fragmentation patterns (modified from [28]) of (a) compound 6 and (b) compound 1, showing characteristic fragments and respective measured m/z values.






Figure S2: +ESI-qTOF chromatograms of (a) compound 1, (b) 1 after 72 h of incubation during the anthelmintic assay without addition of ascorbic acid and (c) plus 0.01 % ascorbic acid. Arrows indicate formation of minor side products 1 and 2 during incubation time. Formation of 2 was generally prevented by addition of ascorbic acid.

Figure S3: 1D- and 2D-NMR spectra of compound **15**.


a) ^1H NMR spectrum of compound **15** (D_2O , 600 MHz).




b) ^{13}C NMR spectrum of compound **15** (D_2O , 150 MHz).




c) COSY spectrum of compound **15** (D₂O, 600 MHz).



d) HSCQ spectrum of compound **15** (D₂O, 600 MHz).



e) HMBC spectrum of compound 15 (D₂O, 600 MHz).



f) NOESY spectrum of compound 15 (D₂O, 600 MHz).






Figure S4: 1D- and 2D-NMR spectra of compound **17**.

a) ^1H NMR spectrum of compound **17** (D_2O , 600 MHz).


spl_5573_PROTON_01




b) HSCQ spectrum of compound **17** (D_2O , 600 MHz).




c) HMBC spectrum of compound 17 (D₂O, 600 MHz).



d) COSY spectrum of compound 17 (D₂O, 600 MHz).



e) TOCSY spectrum of compound 17 (D₂O, 600 MHz).



f) NOESY spectrum of compound 17 (D₂O, 600 MHz).






Figure S5: 1D- and 2D-NMR spectra of compound **18**.

a) ^1H NMR spectrum of compound **18** (D_2O , 600 MHz).


spi_5876_PROTON_01




b) HSCQ spectrum of compound **18** (D_2O , 600 MHz).




c) HMBC spectrum of compound 18 (D₂O, 600 MHz).



d) COSY spectrum of compound 18 (D₂O, 600 MHz).



e) TOCSY spectrum of compound 18 (D₂O, 600 MHz).



f) H2BCAD spectrum of compound 18 (D₂O, 600 MHz).






Figure S6: 1D- and 2D-NMR spectra of compound **19**.


a) ^1H NMR spectrum of compound **19** (D_2O , 600 MHz).



b) HSCQ spectrum of compound **19** (D_2O , 600 MHz).



c) HMBC spectrum of compound **19** (D₂O, 600 MHz).



d) COSY spectrum of compound **19** (D₂O, 600 MHz).




Figure S7: ^1H NMR spectrum of compound **1** (CD_3OD , 600 MHz, 280 K). Peak assignment was performed for major rotamers only.




Figure S8: ^1H NMR spectrum of compound **2** (CD_3OD , 600 MHz, 280 K). Peak assignment was performed for major rotamers only.




Figure S9: ^1H NMR spectrum of compound **3** (CD_3OD , 600 MHz, 280 K). Peak assignment was performed for major rotamers only.




Figure S10: ^1H NMR spectrum of compound **3a** (CDCl_3 , 600 MHz, 299 K). Peak assignment was performed for major rotamers only. 2.34 – 1.22 ppm: signals of acetate groups.




Figure S11: ^1H NMR spectrum of compound **4** (CD_3OD , 600 MHz, 280 K). Peak assignment was performed for major rotamers only.




Figure S12: ^1H NMR spectrum of compound **5** (CD_3OD , 600 MHz, 280 K). Peak assignment was performed for major rotamers only.




Figure S13: ^1H NMR spectrum of compound **6** (CD_3OD , 600 MHz, 280 K).




Figure S14: ^1H NMR spectrum of compound **7** (spectrum 2, top) compared to a spectrum of the reference compound (spectrum 1, bottom), (CDCl_3 , 600 MHz).




Figure S15: ^1H NMR spectrum of compound **8** (CDCl_3 , 600 MHz).




Figure S16: ^1H NMR spectrum of compound **9** (CD_3OD , 600 MHz).




Figure S17: ^1H NMR spectrum of compound **10** (acetone- d_6 , 600 MHz).




Figure S18: ^1H NMR spectrum of compound **11** (acetone- d_6 , 600 MHz).




Figure S19: ^1H NMR spectrum of compound **12** (acetone- d_6 , 600 MHz).




Figure S20: ^1H NMR spectrum of compound **13** (acetone- d_6 , 600 MHz).




Figure S21: ^1H NMR spectrum of compound **14** (CD_3OD , 600 MHz).




Figure S22: ^1H NMR spectrum of compound **16** (D_2O , 600 MHz).

